Cancer Vaccines

Survival Influenced by Immune Response to Polymorphic Epithelial Mucin

Published in Cancer Weekly, March 28th, 2000

Survival in breast cancer patients may be linked to a natural humoral immune response to polymorphic epithelial mucin, suggested researchers from The Netherlands.

"Polymorphic epithelial mucin (PEM or MUCI) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma," stated S. von Mensdorff-Pouilly and colleagues, Vrije University Amsterdam, The Netherlands. "The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease."

von Mensdorff-Pouilly et al. published the results of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry